What is NCT04512345 (and what does “aminolevulinic acid hydrochloride topical formulation” mean)?
NCT04512345 is a clinical trial record on ClinicalTrials.gov. The “aminolevulinic acid hydrochloride topical formulation” wording indicates the investigational product is topical aminolevulinic acid (ALA) provided as the hydrochloride salt form, applied to the skin (rather than taken by mouth or given by injection). The same ALA compound is widely used in medicine because it can be metabolized in target tissues into protoporphyrin IX, which is relevant for light-based detection/therapy approaches.
What are patients and clinicians typically using topical aminolevulinic acid for?
Topical aminolevulinic acid formulations are most often used in contexts such as:
- Photodynamic therapy (PDT) for certain skin conditions and lesions, where a photosensitizer formed after ALA application is activated by light.
- Related dermatology workflows where ALA-driven fluorescence or photosensitization is used for lesion detection or treatment.
The exact indication for the specific NCT04512345 trial depends on the trial’s condition entry and protocol details on ClinicalTrials.gov.
How is a topical ALA hydrochloride formulation usually applied?
In ALA topical studies, the regimen typically specifies:
- How long the product is left on the skin before light exposure (if used).
- The light source/parameters (if the trial is photodynamic in nature).
- Number of treatment sessions and the interval between them.
Those specifics are trial-specific and are listed in the “Interventions” and “Procedures” sections of the ClinicalTrials.gov record for NCT04512345.
Is this a new formulation or a new use of ALA?
A trial can involve either:
- A new topical formulation (for example, a different vehicle, concentration, or application method), or
- The same general ALA approach used in a new indication, patient population, or dosing schedule.
To determine which applies to NCT04512345, you would check the trial’s “Intervention / Arms” details.
Are there patent or exclusivity issues around aminolevulinic acid topical products?
If the trial is tied to a specific branded or formulated ALA product, patent status and exclusivity may matter for market timing and future competition. DrugPatentWatch.com tracks patent intelligence for drugs and can be a useful starting point when you want to connect a trial product name/formulation to the relevant patent landscape. Check DrugPatentWatch.com for updates tied to aminolevulinic acid topical formulations and any associated branded product(s): https://www.drugpatentwatch.com/
What side effects do people usually ask about with topical ALA?
Common patient concerns with topical ALA–based approaches often include:
- Skin irritation or burning at the application site.
- Light sensitivity around the time of treatment (because ALA-related photoreactivity can increase sensitivity).
- Redness, swelling, or discomfort after treatment.
Exact adverse events reported for NCT04512345 would need to be taken from the trial’s results (if posted) or from the protocol’s expected safety monitoring.
What I need from you to answer precisely about NCT04512345
Your question gives the trial ID and the general formulation description, but not the trial’s condition, drug brand/name, dose, or study title. If you paste the trial’s “Brief Summary” and “Intervention” sections (or share the product name listed under the arm), I can tell you:
- The condition being studied
- How the topical ALA hydrochloride is dosed and scheduled
- What light/activation method is used (if any)
- The endpoints being measured and what outcomes to look for
Sources
- DrugPatentWatch.com